Heart Failure Connect
  • Saved
Health Status Across Major Subgroup of Patients with Heart Failure and Preserved Ejection Fraction - PubMed

Health Status Across Major Subgroup of Patients with Heart Failure and Preserved Ejection Fraction - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36974746/

Health status in patients with HFpEF is impaired, especially in elderly, women, and those with obesity and comorbidities. Empagliflozin improved health status among all key subgroups studied with a greater...

Conclusion: Health status in patients with HFpEF is impaired, especially in elderly, women, and those with obesity and comorbidities. Empagliflozin improved health status among all key subgroups studied with a greater effect in obese patients.

  • Saved
Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events - PubMed

Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36967133/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....

Discussion: The RCTs investigating the effects of the SGLT2 inhibitors found robust results on significant reductions in three-point MACE (MACE-3), HHF, as well as renal function in patients with HF across the range of phenotypes according to LVEF (HFrEF, HFmrEF, and HFpEF). Additionally, a meta-analytic effect of AF as one of the adverse...

  • Saved
Heart Failure and Diabetes: Clinical significance and epidemiology of this two-way association - PubMed

Heart Failure and Diabetes: Clinical significance and epidemiology of this two-way association - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36949650/

People with type 2 diabetes (T2DM) and those with pre-diabetes have an increased risk of heart failure (HF). Longer duration of T2DM correlates with a greater risk of HF, but...

Conclusions/Relevance: Most recently the SGLT-2 receptor blockers have shown efficacy in both HFrEF and HFpEF. The only other oral or injectable diabetes agent shown to improve outcomes in both is metformin.

  • Saved

Conclusions/Relevance: Critical gaps in implementation of exercise-based therapies for patients with HFpEF, including exercise setting, training modalities, combinations with other strategies such as diet and medications, long-term adherence, incorporation of innovative and more accessible delivery methods, and management of recently...

  • Saved
Galectin-3 and HFpEF: Clarifying an Emerging Relationship

Galectin-3 and HFpEF: Clarifying an Emerging Relationship

Source : https://www.eurekaselect.com/article/130278

Introduction: HFpEF is a leading cause of death whose burden is projected to increase in the coming decades. The aim of this paper is to interrogate the relationship between levels...

Conclusion: Given the paucity of effective therapeutics for HFpEF, galectin-3 shows promise as a possible HFpEF-linked biomarker that may, with further study, inform and predict treatment course to reduce morbidity and mortality.